Janssen Biotech ’s Tremfya receives FDA approval for plaque psoriasis treatment

The US Food and Drug Administration (FDA) has granted approval for Janssen Biotech ’s Tremfya (guselkumab) to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news